The medication cycle of Benambax for injection needs to be personalized according to the type of infection and the patient's immune status, usually with pathogen clearance and clinical symptom relief as the treatment endpoint. The following provides specific explanations on different indications for treatment courses, adjustments for special populations, and key points for treatment monitoring.

1. Different indications for treatment courses

(1) Pneumocystis carinii pneumonia: The standard course of treatment for immunocompromised patients is 21 days, requiring daily intravenous administration. In severe cases, it can be extended to 28 days.

(2) Black fever: The treatment course for skin type is 10-15 days, for visceral type it requires continuous medication for 20 days, and for those with HIV infection, it needs to be extended to 4 weeks.

Adjustment for Special Groups 2

(1) Renal insufficiency: When the creatinine clearance rate is less than 50ml/min, the course of treatment is prolonged by 25%, and blood drug concentration needs to be closely monitored.

(2) Child patients: After adjusting the dosage according to body weight, the treatment course is the same as that of adults, but the maximum daily dose does not exceed 4mg/kg.

3 Key points for treatment monitoring

(1) Efficacy evaluation: After 7 days of medication, a re examination of pathogen testing is required. If the result is negative, the entire treatment process still needs to be completed.

(2) Toxicity monitoring: Blood routine and liver and kidney function tests are conducted weekly. If there are grade III or above adverse reactions, the course of treatment should be interrupted.